The dissolution profile of inhaled drugs underpins therapeutic efficacy and is an area of increasing regulatory scrutiny, particularly for the demonstration of bioequivalence in a generic. The new IDDC works efficiently with standard inhaler test equipment to reproducibly capture a representative sample for dissolution testing by US Pharmacopoeia (USP) Method 2, an apparatus routinely used for tablets.
Following deposition, inhaled drug particles must dissolve and permeate into the lung tissue to reach their site of action. Dissolution testing elucidates this behaviour and is particularly important for modified release or low solubility compounds, or when establishing parity between a test (generic) and reference (innovator) product. Currently published dissolution methods offer limited flexibility with respect to the particle size ranges analysed, tend to suffer from poor reproducibility and have low discriminating power. Inconsistent sample collection is a common problem.
The new IDDC accommodates a range of inlet components routinely used to measure ...
